Jabir Nasimudeen R, Kamal Mohammad A, Abuzenadah Adel Mohammad, Gan Siew Hua, Alama Mohammed Nabil, Baeesa Saleh S, Tabrez Shams
King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
CNS Neurol Disord Drug Targets. 2014 Mar;13(2):299-304. doi: 10.2174/18715273113126660145.
Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two devastating diseases that are currently incurable. Epidemiological, clinical and pathological evidence has confirmed the co-existence of these two disorders. Moreover, there has been promising progress made in the identification of the pathological linkage between T2DM and AD in the last decade. Hence, developing common treatment strategies for these diseases is important. Currently, enzyme targeting is a potential strategy to cure many diseases. In this communication, we tried to summarize the single enzymetargeted therapeutic approach for the treatment of AD and T2DM. This field of research continues to be active and progressive in identifying many promising enzymes that are involved in both diseases. Based on this review article, we also believe that enzyme inhibition is a promising and reliable strategy for the treatment of many incurable diseases. In the future, we expect that the scientific community will be able to develop common enzyme inhibitors for the treatment of both AD and T2DM.
阿尔茨海默病(AD)和2型糖尿病(T2DM)是目前无法治愈的两种毁灭性疾病。流行病学、临床和病理学证据已证实这两种疾病并存。此外,在过去十年中,在确定T2DM与AD之间的病理联系方面取得了有前景的进展。因此,为这些疾病制定共同的治疗策略很重要。目前,酶靶向是治疗许多疾病的一种潜在策略。在本通讯中,我们试图总结针对AD和T2DM治疗的单一酶靶向治疗方法。该研究领域在确定许多与这两种疾病都有关的有前景的酶方面持续活跃且不断进步。基于这篇综述文章,我们也认为酶抑制是治疗许多无法治愈疾病的一种有前景且可靠的策略。未来,我们期望科学界能够开发出用于治疗AD和T2DM的共同酶抑制剂。